Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives

Hypertension

Volumn 30, Issue 6, 1997, Pages 1566-1571

  Ricci, Alberto ^a   Bronzetti, Elena ^a   Mulatero, Paolo ^b   Schena, Marina ^b   Veglio, Franco ^b   Amenta, Francesco ^c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

^d Dipto Sci Farmacologiche Med S   (Italy)

Author keywords

D3 receptors; Dopamine; Hypertension marker; Mononuclear cells; Radioligand binding assay

Indexed keywords

ADRENALIN; ALDOSTERONE; DOPAMINE; DOPAMINE 3 RECEPTOR; NORADRENALIN; RENIN; 7 HYDROXY 2 N,N DIPROPYLAMINOTETRALIN; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DRD3 PROTEIN, HUMAN; TETRALIN DERIVATIVE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD PRESSURE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE MARKER; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; BINDING COMPETITION; BLOOD; CLASSIFICATION; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOASSAY; REFERENCE VALUE;

ADULT; ALDOSTERONE; BINDING, COMPETITIVE; BLOOD PRESSURE; DOPAMINE; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NOREPINEPHRINE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REFERENCE VALUES; RENIN; TETRAHYDRONAPHTHALENES;

EID: 0030608807     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.6.1566     Document Type: Article

References (48)

1. Amenta F. Density and distribution of dopamine receptors in the cardiovascular system and in the kidney. J Auton Pharamacol. 1990; 1(suppl 1):s11-s18.
2. Lokhandwala MF, Hegde SS. Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion. Pharmacol Toxicol. 1990;66:237-243.
3. Goldberg LI, Kohli JD. Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol. 1979;3: 447-452.
4. Cheung P-Y, Barrington KJ. Renal dopamine receptors: mechanisms of action and developmental aspects. Cardiovasc Res. 1996; 31:2-6.
5. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci. 1992;13:61-69.
6. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 1993;16:299-321.
7. Montastruc JL, Damase-Michel C, Montastruc P. Dopamine and hypertension. In: Peripheral Dopamine Pathophysiology. Boca Raton, FL: CRC Press; 1990:163-171.
8. Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ Jr, Canessa LM, Jose PA. Renal dopamine-1 receptor mRNA and organ specificity of the dopamine-1 receptor/adenylyl cyclase coupling defect in the spontaneously hypertensive rat. Am J Physiol. 1993;264:R726-R732.
9. Van den Buuse M, Jones CR, Wagner J. Brain dopamine D2 receptor mechanisms in spontaneously hypertensive rats. Brain Res Bull. 1992;28:289-297.
10. Os I, Kjeldsen SE, Westheim A, Aakesson I, Norman N, Enger E, Hjermann I, Eide I. Decreased central dopaminergic activity in essential hypertension. J Hypertens. 1987;5:191-197.
11. Kuchel OG, Kuchel GA. Peripheral dopamine in pathophysiology of hypertension: interaction with aging and lifestyle. Hypertension. 1991;18:709-721.
12. Kuchel O. Dopamine and hypertension. Curr Opin Cardiol. 1990; 5:494-600.
13. Clark BA, Rosa RM, Epstein FH, Young JB, Landsberg L. Altered dopaminergic responses in hypertension. Hypertension. 1992;19: 589-594.
14. Clark BA. Postjunctional dopamine receptor stimulants. In: Peripheral Dopamine Pathophysiology. Boca Raton, Fla: CRC Press; 1990: 253-265.
15. Clark BA. Prejunctional dopamine receptor stimulants. In Peripheral Dopamine Pathophysiology. Boca Raton, Fla: CRC Press; 1990:267-306.
16. Miura Y, Takahashi M, Sano N, Ohzeki T, Meguro Y, Sugawara T, Noshiro T, Watanabe H, Shimazu K, Abe K, Yoshinaga K. Plasma free dopamine in human hypertension. Clin Exp Hypertens. 1989;1: 227-236.
17. Miura Y, Watanabe T, Noshiro T, Shimizu K, Kusakari T, Akama H, Shibukawa S, Miura W, Ohzeki T, Takahashi M, Sano N. Plasma free dopamine: physiological variability and pathophysiology significance. Hypertens Res. 1995;18(suppl I):S65-S72.
18. Yoshizumi M, Ishimura Y, Masuda Y, Ohuchi T, Katoh I, Houchi H, Oka M. Physiological significance of plasma sulfoconjugated dopamine: experimental and clinical studies. Hypertens Res. 1995; 18(suppl I)S101-S106.
19. Kuchel O, Shigetomi S. Defective dopamine generation from dihydroxyphenylamine in stable essential hypertensive patients. Hypertension. 1992;19:634-638.
20. Kuchel O. Genetic determinants of dopaminergic activity: potential role in blood pressure regulation. Hypertens Res. 1995;18(suppl I)S1-S10.
21. Kuchel O, Shigetomi S. Dopaminergic abnormalities in hypertension associated with moderate renal insufficiency. Hypertension. 1994;23(suppl I):I-240-I-245.
22. Kuchel O, Shigetomi S. Dopamine deficiency: its potential contribution to chronic renal failure complicating hypertension. Hypertens Res. 1995;18(suppl I):S183-S185.
23. 3H]-spiroperidol binding sites in mammalian lymphocytes. Life Sci. 1980;26:1139-1148.
24. Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudo genes. FEBS Lett. 1992;314:23-25.
25. Santambrogio L, Lipartiti M, Bruni A, Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol. 1993; 45:113-120.
26. Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T. Expression of the dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun. 1993;194:368-374.
27. 5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol. 1994;53:1-7.
28. 3H]-7-OH-DPAT. J Neuroimmunol. 1995;58: 139-144.
29. Fifth Report of the Joint National Committee Guidelines on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). Arch Int Med. 1993;153:154-183.
30. Amenta F, Coppola L, Gallo P, Ferrante F, Forlani A, Monopoli A, Napoleone P. Autoradiographic localization of β-adrenergic receptors in human large coronary arteries. Circ Res. 1991;68: 1591-1599.
31. Blankesteijn WM, Graafsma SJ, van Tits LJH, Hectors MPC, Thien T. Adrenoceptors on blood cells in patients with primary hypertension: correlation with blood pressure and related variables. J Hypertens. 1993;11:995-1002.
32. Weicker H, Faraudi M, Hagele H, Pluto R. Electrochemical detection of catecholamines in urine and plasma after separation with high pressure liquid chromatography. Clin Chem Acta. 1984; 141:17-25.
33. McPherson GA. RADLIG: a Collection of Programs for the Analysis of Radioligand Binding Experiments. Cambridge, Mass: Biosoft; 1994.
34. Jose PA, Felder RA. What we can learn from the selective manipulation of dopaminergic receptors about the pathogenesis and treatment of hypertension? Curr Opin Nephrol Hypertens. 1996;5: 447-451.
35. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994;15:264-270.
36. Sokoloff P, Martres MP, Giros B, Boithenet ML, Schwartz JC. The third dopamine receptor (D3) as a novel target for antipsychotic. Biochem Pharmacol. 1992;43:659-666.
37. 3H]-spiroperidol binding in striatum of spontaneously hypertensive rat (SHR). Eur J Pharmacol. 1982;82:243-244.
38. Kujirai K, Przdborski S, Kostic V, Jackson-Lewis V, Fahn S, Cadet JL. Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat. Brain Res Bull. 1990;25: 703-709.
39. Watanabe T, Noshiro T, Akama H, Kusakari T, Shibukawa S, Miura W, Abe K, Miura Y. Effect of dexamethasone on plasma free dopamine: dopaminergic modulation in hypertensive patients. Hypertens Res. 1995;18(suppl I):S197-S198.
40. Ohbu K, Felder RA. Nephron segment specificity of dopamine receptor/adenylyl cyclase defect in spontaneous hypertension. Am J Physiol. 1993;264:F274-F279.
41. Felder RA, Yamaguchi I, Horiuchi A, Jose PA, Carey RM. A molecular approach to the study of renal dopamine receptors in hypertension. Adv Biosci. 1993;88:155-164.
42. Kinoshita S, Sidhu A, Felder RA. Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rats. J Clin Invest. 1989;84: 1849-1856.
43. + exchanger in spontaneously hypertensive rats. Am J Physiol. 1991;261:F526-F536.
44. Chen CJ, Vyas SJ, Eichberg J, Lokhandwala MF. Diminished phospholipase C activation by dopamine in spontaneously hypertensive rats. Hypertension. 1992;19:102-108.
45. Gao D-Q, Canessa LM, Mouradian MM, Jose PA. Expression of the D2 subfamily of dopamine receptor genes in the kidney. Am J Physiol. 1994;35:F646-F650.
46. O'Connel DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension. 1997;29:115-122.
47. 5 receptor expression is unchanged in peripheral blood lymphocytes in essential hypertension. Clin Exp Hypertens. 1995;17:1157-1172.
48. Côté L, Crutcher MD. The basal ganglia. In: Kandel E, Schwartz JH, Jessell TM, eds. Principles of Neural Science. New York, NY: Elsevier; 1991:647-659.